371 related articles for article (PubMed ID: 25661353)
1. Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
Lv J; Fu Z; Shi M; Xia K; Ji C; Xu P; Lv M; Pan B; Dai L; Xie H
Biomed Pharmacother; 2015 Feb; 69():162-9. PubMed ID: 25661353
[TBL] [Abstract][Full Text] [Related]
2. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
4. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
5. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
6. Systematic analysis of gene expression pattern in has-miR-197 over-expressed human uterine leiomyoma cells.
Ling J; Wu X; Fu Z; Tan J; Xu Q
Biomed Pharmacother; 2015 Oct; 75():226-33. PubMed ID: 26311392
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of microRNAs expressed in human breast cancer chemo-resistant MCF-7/Adr cells by Solexa deep-sequencing technology.
Xu P; Wang L; Huang L; Li W; Lv S; Lv M; Ma J; Zhou Q; Wu X; Fu Z; Lu C; Yin H
Biomed Pharmacother; 2015 Oct; 75():173-8. PubMed ID: 26293775
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
Yang G; Wu D; Zhu J; Jiang O; Shi Q; Tian J; Weng Y
Oncol Rep; 2013 Aug; 30(2):877-89. PubMed ID: 23760062
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR].
Cui XY; Guo YJ; Yao HR
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1813-5. PubMed ID: 18971180
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
Sun FD; Wang PC; Luan RL; Zou SH; Du X
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
[TBL] [Abstract][Full Text] [Related]
12. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
13. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.
Feng X; Zhao L; Gao S; Song X; Dong W; Zhao Y; Zhou H; Cheng L; Miao X; Jia L
Gene; 2016 Mar; 578(2):232-41. PubMed ID: 26701615
[TBL] [Abstract][Full Text] [Related]
14. miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27(kip1) expression.
Wang DD; Li J; Sha HH; Chen X; Yang SJ; Shen HY; Zhong SL; Zhao JH; Tang JH
Gene; 2016 Sep; 590(1):44-50. PubMed ID: 27282281
[TBL] [Abstract][Full Text] [Related]
15. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
16. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
17. Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway.
Huang Q; Wu YY; Xing SJ; Yu ZW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5285-5292. PubMed ID: 31298380
[TBL] [Abstract][Full Text] [Related]
18. Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression.
Zhou S; Li J; Xu H; Zhang S; Chen X; Chen W; Yang S; Zhong S; Zhao J; Tang J
Gene; 2017 Jul; 622():1-12. PubMed ID: 28431975
[TBL] [Abstract][Full Text] [Related]
19. Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer.
He DX; Gu XT; Li YR; Jiang L; Jin J; Ma X
FEBS J; 2014 Oct; 281(20):4718-30. PubMed ID: 25156775
[TBL] [Abstract][Full Text] [Related]
20. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
